Company intelligence / Profile preview

Vircell

Granada, Andalusia, Spainvircell.com ↗

Ownership: Private
Development stage: Other

Overview

Vircell has over three decades of experience developing and manufacturing ready-to-use reagents for diagnosing human infectious diseases. Its portfolio includes more than 500 products covering bacteria, viruses, parasites and fungi using techniques like ELISA, chemiluminescence immunoassays (CLIA), direct/indirect immunofluorescence assays (IFA), cell culture methods and advanced molecular biology tools such as real-time PCR. Their products are exported to over 90 countries worldwide. All IVD products are CE marked.

Therapeutic areas: Infectious Diseases
Modalities: AntibodyMolecular BiologyProteinCell culture-based reagentsChemiluminescence immunoassay (CLIA)Immunocapture agglutinationSmall molecule
Industry: Molecular Diagnostics

Partnerships

Not specifically listed; distributes through global partners/distributors

Beyond the preview

Go deeper on Vircell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vircell.

Explore the full profile